Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to -$34.9 million.

  • Sangamo Therapeutics' Consolidated Net Income fell 42730.51% to -$34.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.9 million, marking a year-over-year increase of 1923.09%. This contributed to the annual value of -$97.9 million for FY2024, which is 6201.35% up from last year.
  • Latest data reveals that Sangamo Therapeutics reported Consolidated Net Income of -$34.9 million as of Q3 2025, which was down 42730.51% from -$20.0 million recorded in Q2 2025.
  • Sangamo Therapeutics' Consolidated Net Income's 5-year high stood at $21.1 million during Q1 2023, with a 5-year trough of -$114.5 million in Q2 2023.
  • Over the past 5 years, Sangamo Therapeutics' median Consolidated Net Income value was -$44.0 million (recorded in 2022), while the average stood at -$42.7 million.
  • As far as peak fluctuations go, Sangamo Therapeutics' Consolidated Net Income tumbled by 306326.26% in 2021, and later skyrocketed by 14800.88% in 2023.
  • Quarter analysis of 5 years shows Sangamo Therapeutics' Consolidated Net Income stood at -$37.5 million in 2021, then plummeted by 38.63% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then skyrocketed by 61.2% to -$23.4 million in 2024, then plummeted by 49.3% to -$34.9 million in 2025.
  • Its Consolidated Net Income stands at -$34.9 million for Q3 2025, versus -$20.0 million for Q2 2025 and -$30.6 million for Q1 2025.